Eris Lifesciences Ltd, founded in 2007 and headquartered in Ahmedabad, Gujarat, is a leading Indian pharmaceutical company focused on the domestic branded formulations market. It has a strong presence in chronic and sub-chronic therapies, particularly in the cardio-metabolic segment, while also expanding into dermatology, neuropsychiatry, women’s health, and nephrology. The company follows a pure-play business model, exclusively targeting the Indian market.
Eris operates with integrated manufacturing facilities in Guwahati and Gujarat and is heavily invested in research and development. It conducts India-centric studies like the India Heart Study and the India Diabetes Study, which provide valuable data for disease management. Eris Lifesciences is dedicated to advancing therapies and patient care initiatives, particularly in managing chronic lifestyle-related diseases.
Recent News on ERIS Lifesciences Ltd
Eris Lifesciences Ltd has been making significant strategic moves in recent times, aiming to strengthen its market position and diversify its portfolio. A key development is its recent acquisition of Biocon Biologics’ India-branded formulations business for ₹1,242 crore. This acquisition marks a crucial step for Eris as it enters the injectables market, a segment that is rapidly growing in India due to increasing demand for advanced and effective treatment options. The deal also bolsters Eris’s presence in the insulin segment, enhancing its product offerings in the management of diabetes—a major focus area for the company given its strong presence in the cardio-metabolic domain. The integration of Biocon Biologics’ formulations business is expected to expand Eris’s footprint in the Indian pharmaceutical market, bringing in a broader range of products and therapeutic capabilities.
In another significant move, ChrysCapital, a prominent private equity firm, recently exited Eris Lifesciences by selling its entire 7.27% stake for ₹1,187 crore. ChrysCapital’s exit represents one of the larger private equity withdrawals in the Indian pharmaceutical sector in recent years, reflecting confidence in Eris’s market value and future prospects. This development has increased Eris’s visibility in the market, potentially attracting new investors interested in its growth trajectory. Both these moves—the acquisition of Biocon Biologics’ business and the exit of ChrysCapital—highlight Eris Lifesciences’ dynamic strategy to consolidate its market position, expand into new segments, and continue its growth momentum in the competitive Indian pharmaceutical landscape.
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | |
| Promoters + | 52.86% | 54.91% | 54.90% | 54.90% | 54.88% |
| FIIs + | 13.78% | 13.20% | 13.13% | 14.27% | 14.59% |
| DIIs + | 10.73% | 14.52% | 14.55% | 15.63% | 16.23% |
| Public + | 22.63% | 17.37% | 17.41% | 15.20% | 14.30% |
| No. of Shareholders | 44,169 | 42,245 | 46,496 | 51,753 | 44,176 |
The shareholding pattern of Eris Lifesciences Ltd has undergone some interesting shifts from June 2023 to June 2024. Promoter holdings remained consistently strong, rising from 52.86% in June 2023 to a peak of 54.91% in September 2023, before slightly declining to 54.88% by June 2024. Foreign Institutional Investors (FIIs) initially reduced their stake from 13.78% in June 2023 to 13.13% by December 2023, but later increased it to 14.59% in June 2024, signaling renewed interest. Domestic Institutional Investors (DIIs) increased their holdings significantly from 10.73% in June 2023 to 16.23% in June 2024, reflecting growing confidence in the company’s performance. Conversely, the public shareholding dropped from 22.63% in June 2023 to 14.30% in June 2024, suggesting a shift towards more concentrated ownership. The number of shareholders fluctuated, reaching a high of 51,753 in March 2024 before falling back to 44,176 by June 2024, indicating a period of dynamic changes in the investor base.
Below are the trading platforms that you can use to purchase Eris Lifesciences Ltd shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
| When | Maximum Price | Minimum Price |
| September 2024 | 1,482.95 | 1,289.53 |
| October 2024 | 1,468.27 | 1,276.76 |
| November 2024 | 1,527.00 | 1,327.83 |
| December 2024 | 1,542.27 | 1,341.11 |
As we approach the end of 2024, Eris Lifesciences is projected to experience fluctuations in its stock prices. In September 2024, the maximum price is anticipated to reach around ₹1,482.95, with the minimum expected to be ₹1,289.53. Moving into October, the maximum price is likely to adjust slightly lower to ₹1,468.27, while the minimum could be around ₹1,276.76. As we step into November 2024, the maximum price for Eris Lifesciences might climb to ₹1,527.00, with a minimum of ₹1,327.83. Finally, by December 2024, the maximum price could further increase to ₹1,542.27, while the minimum is expected to stabilize around ₹1,341.11.
| When | Maximum Price | Minimum Price |
| January 2025 | 1,557.69 | 1,198.23 |
| February 2025 | 1,573.43 | 1,210.33 |
| March 2025 | 1,606.47 | 1,235.75 |
| April 2025 | 1,590.57 | 1,223.51 |
| May 2025 | 1,544.24 | 1,187.88 |
| June 2025 | 1,613.73 | 1,241.33 |
| July 2025 | 1,582.09 | 1,216.99 |
| August 2025 | 1,631.02 | 1,254.63 |
| September 2025 | 1,650.59 | 1,269.68 |
| October 2025 | 1,693.51 | 1,302.70 |
| November 2025 | 1,735.84 | 1,335.26 |
| December 2025 | 1,813.96 | 1,395.35 |
In 2025, Eris Lifesciences’ stock is anticipated to fluctuate significantly. Starting January, the stock may reach a maximum of ₹1,557.69 and a minimum of ₹1,198.23. By December, it is projected to peak at ₹1,813.96, with a minimum of ₹1,395.35.
| When | Maximum Price | Minimum Price |
| January 2026 | 1,868.37 | 1,437.21 |
| February 2026 | 1,821.67 | 1,401.28 |
| March 2026 | 1,858.10 | 1,429.31 |
| April 2026 | 1,896.02 | 1,458.48 |
| May 2026 | 1,877.25 | 1,444.04 |
| June 2026 | 1,924.18 | 1,480.14 |
| July 2026 | 1,886.45 | 1,451.11 |
| August 2026 | 1,944.79 | 1,495.99 |
| September 2026 | 1,983.69 | 1,525.91 |
| October 2026 | 2,035.26 | 1,565.59 |
| November 2026 | 2,086.15 | 1,604.73 |
| December 2026 | 2,138.30 | 1,644.85 |
| When | Maximum Price | Minimum Price |
| January 2027 | 2,159.68 | 1,661.29 |
| February 2027 | 2,215.06 | 1,703.89 |
| March 2027 | 2,301.45 | 1,770.34 |
| April 2027 | 2,256.32 | 1,735.63 |
| May 2027 | 2,190.60 | 1,685.08 |
| June 2027 | 2,289.18 | 1,760.91 |
| July 2027 | 2,244.29 | 1,726.38 |
| August 2027 | 2,313.70 | 1,779.77 |
| September 2027 | 2,394.68 | 1,842.06 |
| October 2027 | 2,456.95 | 1,889.96 |
| November 2027 | 2,518.37 | 1,937.21 |
| December 2027 | 2,581.33 | 1,985.64 |
| When | Maximum Price | Minimum Price |
| January 2028 | 2,632.96 | 2,025.35 |
| February 2028 | 2,700.47 | 2,077.28 |
| March 2028 | 2,805.78 | 2,158.30 |
| April 2028 | 2,750.77 | 2,115.98 |
| May 2028 | 2,670.65 | 2,054.35 |
| June 2028 | 2,790.83 | 2,146.79 |
| July 2028 | 2,736.11 | 2,104.70 |
| August 2028 | 2,820.73 | 2,169.79 |
| September 2028 | 2,919.45 | 2,245.73 |
| October 2028 | 2,995.36 | 2,304.12 |
| November 2028 | 3,070.24 | 2,361.73 |
| December 2028 | 3,147.00 | 2,420.77 |
| When | Maximum Price | Minimum Price |
| January 2029 | 3,209.94 | 2,469.18 |
| February 2029 | 3,292.25 | 2,532.50 |
| March 2029 | 3,420.64 | 2,631.26 |
| April 2029 | 3,353.57 | 2,579.67 |
| May 2029 | 3,255.90 | 2,504.54 |
| June 2029 | 3,402.41 | 2,617.24 |
| July 2029 | 3,335.70 | 2,565.92 |
| August 2029 | 3,438.86 | 2,645.28 |
| September 2029 | 3,559.22 | 2,737.86 |
| October 2029 | 3,651.76 | 2,809.05 |
| November 2029 | 3,743.06 | 2,879.27 |
| December 2029 | 3,836.63 | 2,951.26 |
| When | Maximum Price | Minimum Price |
| January 2030 | 3,913.37 | 3,010.28 |
| February 2030 | 4,013.71 | 3,087.47 |
| March 2030 | 4,170.24 | 3,207.88 |
| April 2030 | 4,088.47 | 3,144.98 |
| May 2030 | 3,969.39 | 3,053.38 |
| June 2030 | 4,148.02 | 3,190.78 |
| July 2030 | 4,066.68 | 3,128.22 |
| August 2030 | 4,192.46 | 3,224.97 |
| September 2030 | 4,339.19 | 3,337.84 |
| October 2030 | 4,452.01 | 3,424.62 |
| November 2030 | 4,563.31 | 3,510.24 |
| December 2030 | 4,677.39 | 3,597.99 |
In 2030, Eris Lifesciences’ stock is projected to experience significant price fluctuations. Starting in January, the stock is expected to reach a maximum of ₹3,913.37 and a minimum of ₹3,010.28. By December, the price may climb to a peak of ₹4,677.39, with a low of ₹3,597.99. Throughout the year, the stock is anticipated to show strong growth.
Eris Lifesciences Ltd Financial Condition: Last 5 Years
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
| Sales + | 1,074 | 1,212 | 1,347 | 1,685 | 2,009 | 2,262 |
| Expenses + | 702 | 781 | 858 | 1,146 | 1,332 | 1,507 |
| Operating Profit | 372 | 431 | 489 | 539 | 677 | 755 |
| OPM % | 35% | 36% | 36% | 32% | 34% | 33% |
| Other Income + | 12 | 9 | 22 | 9 | 22 | 24 |
| Interest | 2 | 2 | 4 | 26 | 85 | 128 |
| Depreciation | 50 | 43 | 65 | 117 | 183 | 218 |
| Profit before tax | 331 | 394 | 442 | 405 | 431 | 434 |
| Tax % | 11% | 10% | 8% | 8% | 8% | |
| Net Profit + | 297 | 355 | 406 | 374 | 397 | 393 |
| EPS in Rs | 21.84 | 26.16 | 29.88 | 28.1 | 28.82 | 27.95 |
| Dividend Payout % | 13% | 21% | 20% | 26% | 0% |
Eris Lifesciences Ltd has demonstrated a strong financial performance over the years from March 2020 to March 2024, with a clear upward trajectory in key financial metrics. The company’s sales revenue grew consistently from ₹1,074 crore in March 2020 to ₹2,262 crore in the trailing twelve months (TTM) ending March 2024, reflecting a substantial increase in market demand for its products. The operating profit also witnessed a commendable rise from ₹372 crore to ₹755 crore during the same period, although the Operating Profit Margin (OPM) showed some fluctuations, moving between 32% and 36%, indicative of varying cost pressures or strategic spending.
Eris Lifesciences also experienced an increase in its expense structure, with notable rises in both interest expenses and depreciation costs. Interest expenses jumped significantly from ₹2 crore in March 2020 to ₹128 crore in the TTM ending March 2024, suggesting higher borrowing possibly to fund expansion activities or acquisitions. Similarly, depreciation costs increased from ₹50 crore to ₹218 crore, indicating ongoing investments in fixed assets and infrastructure. Despite these increased costs, the company’s profit before tax remained stable, averaging around ₹431 crore, and the net profit saw a gradual increase from ₹297 crore to ₹393 crore, underlining its resilience in managing its financial health amidst a dynamic market environment.
Earnings per share (EPS) also showed resilience, starting at ₹21.84 in March 2020 and ending at ₹27.95 in the TTM of March 2024, despite minor fluctuations. However, the company’s approach to dividend payouts varied, with a peak of 26% in March 2023 but a decision to forego dividends in March 2024, which could reflect a strategic move to retain earnings for future growth initiatives or to bolster its balance sheet. Overall, Eris Lifesciences Ltd has managed to maintain robust growth, balancing revenue expansion with strategic cost management and capital investment.
FAQs
Will ERIS Lifesciences stock price grow in 2024?
Yes, ERIS Lifesciences stock price is expected to grow in 2024. The company’s current share price is around Rs 1,448, and analysts have estimated that ERIS Lifesciences price will reach ₹1,542.27 by the end of 2024.
What future is anticipated for ERIS Lifesciences in 2025?
Analysts expect ERIS Lifesciences stock price to reach Rs 1,813.96 by the end of 2025.
In 2030, ERIS Lifesciences is expected to trade in between ₹3,010.28 and ₹4,677.39.
Also Read
- Jyoti CNC Automation Ltd Share Price Target 2024, 2025 to 2030
- Shipping Corporation of India Ltd Share Price Target 2024, 2025 to 2030
- Reliance Power Ltd Share Price Target 2024, 2025 to 2030
Conclusion: Sustained Growth and Market Leadership for ERIS Lifesciences
In conclusion, Eris Lifesciences Ltd has demonstrated impressive financial growth and stability over the past five years. The company’s sales and operating profits have shown substantial increases, with net profit rising from ₹297 crore to ₹393 crore. Despite higher interest and depreciation costs, Eris Lifesciences has maintained a robust financial health and improved its EPS from ₹21.84 to ₹27.95.
Looking forward, the company is poised for continued growth. The stock price is projected to reach ₹1,542.27 by the end of 2024 and could further climb to ₹1,813.96 by the end of 2025. The long-term outlook is even more promising, with the share price anticipated to range between ₹3,010.28 and ₹4,677.39 by 2030. Eris Lifesciences is well-positioned to leverage its strategic investments and market presence to drive future success.
What did we learn?
- 1 Recent News on ERIS Lifesciences Ltd
- 2 Shareholding Patterns of ERIS Lifesciences
- 3 How to Buy Eris Lifesciences Ltd shares?
- 4 Eris Lifesciences Share Price Target: 2024 to 2030
- 4.1 Eris Lifesciences Share Price Target 2024
- 4.2 Eris Lifesciences Share Price Target 2025
- 4.3 Eris Lifesciences Share Price Prediction 2026
- 4.4 Eris Lifesciences Share Price Target 2027
- 4.5 Eris Lifesciences Share Price Target 2028
- 4.6 Eris Lifesciences Share Price Prediction 2029
- 4.7 Eris Lifesciences Share Price Target 2030
- 5 Eris Lifesciences Ltd Financial Condition: Last 5 Years
- 6 FAQs
- 7 Conclusion: Sustained Growth and Market Leadership for ERIS Lifesciences
